{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:32:29Z","timestamp":1777717949278,"version":"3.51.4"},"reference-count":124,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"CRL Laboratories, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>History has established that many drugs, such as the antibiotics, chemotherapies, and loop diuretics, are capable of inducing both nephrotoxicity and ototoxicity. The exact mechanisms by which cellular damage occurs remain to be fully elucidated. Monitoring the indices of renal function conducted in the Food and Drug Administration\u2019s prescribed set of early investigational new drug (IND)\u2013enabling studies may be the first signs of ototoxicity properties of the new drug candidate. In developing improved and efficacious new molecular entities, it is critically necessary to understand the cellular and molecular mechanisms underlying the potential ototoxic effects as early in the drug development program as possible. Elucidation of these mechanisms will facilitate the development of safe and effective clinical approaches for the prevention and amelioration of drug-induced ototoxicity prior to the first dose in man. Biomarkers for nephrotoxicity in early tier I or tier II nonclinical IND-enabling studies should raise an inquiry as to the need to conduct a full auditory function assay early in the game to clear the pipeline with a safer candidate that has a higher probability of continued therapeutic compliance once approved for distribution.<\/jats:p>","DOI":"10.1177\/1091581819851232","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:08:31Z","timestamp":1561075711000},"page":"265-278","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-7731","authenticated-orcid":false,"given":"David V.","family":"Gauvin","sequence":"first","affiliation":[{"name":"Neurobehavioral Sciences Department, Charles River Laboratories, Inc, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-3972","authenticated-orcid":false,"given":"Zachary J.","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Neurobehavioral Sciences Department, Charles River Laboratories, Inc, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Yoder","sequence":"additional","affiliation":[{"name":"Neurobehavioral Sciences Department, Charles River Laboratories, Inc, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Tapp","sequence":"additional","affiliation":[{"name":"Neurobehavioral Sciences Department, Charles River Laboratories, Inc, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore J.","family":"Baird","sequence":"additional","affiliation":[{"name":"Safety Assessment, Charles River Laboratories, Inc, Mattawan, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,6,20]]},"reference":[{"key":"bibr1-1091581819851232","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Duration Of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing),\n                      S4\n                      . 1998. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S4\/Step4\/S4_Guideline.pdf. Accessed May 13, 2019."},{"key":"bibr2-1091581819851232","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline. Safety Pharmacology Studies For Human Pharmaceuticals, S7A. 2000. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S7A\/Step4\/S7A_Guideline.pdf. Accessed May 13, 2019."},{"key":"bibr3-1091581819851232","unstructured":"International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials And Marketing Authorization For Pharmaceuticals, M3(R2). 2009. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Multidisciplinary\/M3_R2\/Step4\/M3_R2__Guideline.pdf. Accessed May 13, 2019."},{"key":"bibr4-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb00278.x"},{"key":"bibr5-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2016.08.008"},{"key":"bibr6-1091581819851232","first-page":"54","volume":"476","author":"Antonelli AR","year":"1990","journal-title":"Acta Otolaryngol Suppl"},{"key":"bibr7-1091581819851232","first-page":"51","volume":"4","author":"Bendo E","year":"2015","journal-title":"JOAD"},{"key":"bibr8-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.60.052307.120752"},{"key":"bibr9-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0711-0"},{"issue":"1","key":"bibr10-1091581819851232","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/mol.106.022244","volume":"70","author":"Thomas JP","year":"2006","journal-title":"Mol Pharmacol"},{"key":"bibr11-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20172246"},{"key":"bibr12-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208474"},{"key":"bibr13-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00507.2010"},{"key":"bibr14-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006020162"},{"key":"bibr15-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.14.1054"},{"key":"bibr16-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00390.x"},{"key":"bibr17-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/BF01497211"},{"key":"bibr18-1091581819851232","first-page":"489","volume":"9","author":"Sprenger F","year":"1969","journal-title":"Med Welt"},{"key":"bibr19-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2009.12.028"},{"key":"bibr20-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2018.07.007"},{"key":"bibr21-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2015.04.015"},{"key":"bibr22-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.15.11164"},{"key":"bibr23-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00239.2001"},{"key":"bibr24-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1097\/01.ccx.0000145095.90327.f2"},{"key":"bibr25-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1201\/9781420080124"},{"key":"bibr26-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(87)90151-3"},{"key":"bibr27-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00580-003-0479-x"},{"key":"bibr28-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-68511-8_43"},{"key":"bibr29-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-185-42555"},{"issue":"7","key":"bibr30-1091581819851232","first-page":"433","volume":"29","author":"Waner T","year":"1991","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"bibr31-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1258\/002367791780808275"},{"key":"bibr32-1091581819851232","doi-asserted-by":"publisher","DOI":"10.2131\/jts.30.127"},{"issue":"1","key":"bibr33-1091581819851232","first-page":"47","volume":"29","author":"Kobayashi K","year":"2008","journal-title":"J Environ Biol"},{"key":"bibr34-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq029"},{"key":"bibr35-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1080\/01926230390174878"},{"key":"bibr36-1091581819851232","doi-asserted-by":"publisher","DOI":"10.2131\/jts.42.629"},{"key":"bibr37-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2007.12.024"},{"key":"bibr38-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094615"},{"key":"bibr39-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0510-436"},{"key":"bibr40-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2011.615319"},{"key":"bibr41-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192807"},{"key":"bibr42-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00561.x"},{"key":"bibr43-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.7.4135"},{"key":"bibr44-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00285.2002"},{"key":"bibr45-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00433.x"},{"key":"bibr46-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00291.2005"},{"key":"bibr47-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)74811-X"},{"key":"bibr48-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000088027.54400.C6"},{"key":"bibr49-1091581819851232","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04240609"},{"key":"bibr50-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2011.08.019"},{"key":"bibr51-1091581819851232","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04810908"},{"key":"bibr52-1091581819851232","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803282"},{"key":"bibr53-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21468"},{"key":"bibr54-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80496-3"},{"key":"bibr55-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)02110-4"},{"key":"bibr56-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.16.7214-7224.2004"},{"key":"bibr57-1091581819851232","unstructured":"European Medicines Agency. Final Conclusions on the Pilot Joint EMEA\/FDA VXDS Experience on Qualifications of Nephrotoxicity Biomarkers. Doc Ref. EMEA\/679719\/2008, Rev 1. 2009. https:\/\/www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/final-conclusions-pilot-joint-european-medicines-agency\/food-drug-administration-vxds-experience-qualification-nephrotoxicity-biomarkers_en.pdf. Accessed May 13, 2019."},{"key":"bibr58-1091581819851232","unstructured":"European Medicines Agency. Qualification Opinion ILSI\/HESI Submission of Novel Renal Biomarkers for Toxicity. EMA\/CHMP\/SAWO\/283298\/2010. 2010. https:\/\/www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/qualification-opinion-ilsi\/hesi-submission-novel-renal-biomarkers-toxicity_en.pdf. Accessed May 13, 2019."},{"key":"bibr59-1091581819851232","unstructured":"European Medicines Agency. Letter of support for PSTC Translational Drug-Induced Kidney Injury (DIKI) Biomarkers. 2014. EMA\/651243\/2014. https:\/\/www.ema.europa.eu\/documents\/other\/letter-support-predictive-safety-testing-consortium-translational-drug-induced-kidney-injury_en.pdf. Accessed May 13, 2019."},{"key":"bibr60-1091581819851232","unstructured":"European Medicines Agency. Letter of Support for Drug-Induced Renal Tubular Injury Biomarker(s). 2017. EMA\/715025\/2016. https:\/\/www.ema.europa.eu\/documents\/other\/letter-support-drug-induced-renal-tubular-injury-biomarkers_en.pdf. Accessed May 13, 2019."},{"key":"bibr61-1091581819851232","unstructured":"US Food & Drug Administration. Review Submission of the Qualification of Seven Biomarkers of Drug-Induced Nephrotoxicity in Rats. 2008. https:\/\/c-path.org\/\/wp-content\/uploads\/2014\/09\/PSTC-NWG-20080414-FDA-FinalConclusion.pdf. Accessed May 13, 2019."},{"key":"bibr62-1091581819851232","volume-title":"Biomarker Qualification Decision","author":"US Food &amp; Drug Administration","year":"2010"},{"key":"bibr63-1091581819851232","unstructured":"US Food & Drug Administration. Biomarker Letter of Support. 2014. https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/BiomarkerQualificationProgram\/UCM605346.pdf. Accessed May 13, 2019."},{"key":"bibr64-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1080\/00365510802150158"},{"issue":"8","key":"bibr65-1091581819851232","first-page":"791","volume":"47","author":"Appenroth D","year":"1988","journal-title":"Biomed Biochim Acta"},{"key":"bibr66-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-002-0629-5"},{"key":"bibr67-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1624"},{"key":"bibr68-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1293\/tox.2014-0039"},{"key":"bibr69-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310379139"},{"key":"bibr70-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-199-43335"},{"issue":"155","key":"bibr71-1091581819851232","first-page":"290","volume":"23","author":"Anonymous","year":"2014","journal-title":"Prescrire Int"},{"key":"bibr72-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A216"},{"key":"bibr73-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2650-8"},{"key":"bibr74-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1995.tb09952.x"},{"key":"bibr75-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.192"},{"key":"bibr76-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3109\/00498259109039512"},{"key":"bibr77-1091581819851232","author":"Kindgen-Milles D","year":"2018","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"bibr78-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70142-3"},{"key":"bibr79-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178294"},{"key":"bibr80-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.186.79"},{"key":"bibr81-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90744-6"},{"key":"bibr82-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.21.040181.001405"},{"key":"bibr83-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1177\/1091581818761128"},{"key":"bibr84-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90549-5"},{"key":"bibr85-1091581819851232","volume-title":"Free Radicals in Biology and Medicine","author":"Halliwell BH","year":"1995","edition":"2"},{"key":"bibr86-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1515\/JBCPP.2010.21.3.231"},{"key":"bibr87-1091581819851232","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0030-6665(20)30770-2","volume":"26","author":"Rybak LP","year":"1993","journal-title":"Otolaryngol Clin North Amer"},{"key":"bibr88-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.18.040178.001313"},{"key":"bibr89-1091581819851232","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-91-5-744"},{"key":"bibr90-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.11-04-01057.1991"},{"issue":"1","key":"bibr91-1091581819851232","first-page":"81","volume":"5","author":"Gregory JM","year":"2017","journal-title":"Acta Pathol Commun"},{"key":"bibr92-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.05.013"},{"key":"bibr93-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2013.12.002"},{"key":"bibr94-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1038\/nature01059"},{"key":"bibr95-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000001616"},{"key":"bibr96-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1177\/0194599817742093"},{"key":"bibr97-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000001164"},{"key":"bibr98-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.heares.2007.09.001"},{"key":"bibr99-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.1.75"},{"key":"bibr100-1091581819851232","unstructured":"National Institute on Deafness and Other Communication Disorders. NIH Pub No 00-4757. Sudden Deafness. 2003. http:\/\/www.nidcd.nih.gov\/health\/hearing\/pages\/sudden.aspx. Accessed December 30, 2018."},{"key":"bibr101-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079226"},{"key":"bibr102-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4405"},{"key":"bibr103-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3389\/978-2-88945-483-9"},{"key":"bibr104-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2017.08.001"},{"key":"bibr105-1091581819851232","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2017.00338"},{"key":"bibr106-1091581819851232","doi-asserted-by":"publisher","DOI":"10.2174\/157015909789152155"},{"key":"bibr107-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5955(96)00204-3"},{"issue":"2","key":"bibr108-1091581819851232","first-page":"128","volume":"20","author":"Skeith L","year":"2013","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"bibr109-1091581819851232","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry and review staff nonclinical safety evaluation of reformulated drug products and products intended for administration by an alternate route. 2015; https:\/\/www.fda.gov\/media\/72246\/download. Accessed May 13, 2019."},{"key":"bibr110-1091581819851232","first-page":"33","volume-title":"Toxicology Testing Handbook: Principles, Applications and Data Interpretation","author":"Banks C","year":"2001"},{"key":"bibr111-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-017-0423-9"},{"key":"bibr112-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1511701"},{"key":"bibr113-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1016-3"},{"key":"bibr114-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1307-08.2008"},{"key":"bibr115-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.12.044"},{"key":"bibr116-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn418"},{"key":"bibr117-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2008.10.008"},{"key":"bibr118-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1993.01880190054011"},{"key":"bibr119-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176368"},{"key":"bibr120-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2007.061"},{"key":"bibr121-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1159\/000129636"},{"key":"bibr122-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0586-1"},{"key":"bibr123-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1007\/BF03195669"},{"key":"bibr124-1091581819851232","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.3.383"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581819851232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581819851232","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581819851232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:23:49Z","timestamp":1777458229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581819851232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,20]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1177\/1091581819851232"],"URL":"https:\/\/doi.org\/10.1177\/1091581819851232","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,20]]}}}